{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-048761","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.105134+00:00","generated_at":"2026-05-16T03:05:26.725052+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AVITA Medical Q4 revenue down 4% to $17.6M; FY2026 guidance $80-85M","bullets":["Q4 revenue $17.6M (down 4% YoY); gross margin 81.2% vs 87.6%; net loss $11.6M ($0.38/sh) vs $11.6M ($0.44/sh).","Full-year 2025 revenue $71.6M (+11% YoY); net loss $48.6M ($1.74/sh) vs $61.8M ($2.39/sh) in 2024.","Net cash use improved to $5.1M in Q4; cash & marketable securities $18.2M at year-end.","New $60M credit facility with Perceptive Advisors; initial $50M funded, used to repay existing debt.","FY2026 revenue guidance $80-85M (12-19% growth); Cohealyx & PermeaDerm trials fully/significantly enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-048761","json":"https://secwatch.observer/filing/0001193125-26-048761.json","markdown":"https://secwatch.observer/filing/0001193125-26-048761.md","text":"https://secwatch.observer/filing/0001193125-26-048761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/0001193125-26-048761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:05:26.725052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}